<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141409">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124083</url>
  </required_header>
  <id_info>
    <org_study_id>140102</org_study_id>
    <secondary_id>14-CH-0102</secondary_id>
    <nct_id>NCT02124083</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1</brief_title>
  <official_title>Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Niemann-Pick disease type C (NPC) is a lethal, autosomal recessive, lysosomal storage
      disorder characterized by neurodegeneration in early childhood and death in adolescence. The
      causative genes NPC1 (about 95% of cases) and NPC2 (about 5% of cases) are involved in the
      intracellular trafficking of lipids and cholesterol. Mutations on either of these genes lead
      to progressive accumulation of unesterified cholesterol and other lipids in the central
      nervous system (CNS). Vorinostat is a histone deacetylase inhibitor that has been shown in
      vivo to increase mutant NPC1 protein levels and to reverse cellular accumulation of
      unesterified cholesterol. Vorinostat has been labeled by the FDA for treatment of cutaneous
      T-cell lymphoma. In this Phase I, non-randomized, open-label, single-center study, we plan
      to study whether Vorinostat can be repurposed to treat patients with NPC1. Our primary
      objective is to determine the safety and tolerability of Vorinostat in NPC1 disease. Our
      secondary objectives will be to determine biochemical efficacy of Vorinostat to increase
      expression of NPC1 protein and normalize lipid and protein biomarkers.  This study will
      enroll up to 12 NPC1 patients and test the safety of two dose levels (200 and 400 mg).  Drug
      will be administered on a 3 days on/4 days off schedule for 3 months at each dose level.
      Patients will be evaluated at the NIH Clinical Center at 0, 3 and 6 months. Safety will be
      assessed by adverse events (AEs), clinical laboratory tests and physical examinations.
      Biochemical efficacy will be assessed by measurement of serum and cerebral spinal fluid
      biomarkers. Clinical efficacy will be evaluated by audiologic testing, assessment ataxia,
      and swallowing studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Niemann-Pick disease type C (NPC) is a lethal, autosomal recessive, lysosomal storage
      disorder characterized by neurodegeneration in early childhood and death in adolescence. The
      causative genes NPC1 (about 95% of cases) and NPC2 (about 5% of cases) are involved in the
      intracellular trafficking of lipids and cholesterol. Mutations on either of these genes lead
      to progressive accumulation of unesterified cholesterol and other lipids in the central
      nervous system (CNS). Vorinostat is a histone deacetylase inhibitor that has been shown in
      vivo to increase mutant NPC1 protein levels and to reverse cellular accumulation of
      unesterified cholesterol. Vorinostat has been labeled by the FDA for treatment of cutaneous
      T-cell lymphoma. In this Phase I, non-randomized, open-label, single-center study, we plan
      to study whether Vorinostat can be repurposed to treat patients with NPC1. Our primary
      objective is to determine the safety and tolerability of Vorinostat in NPC1 disease. Our
      secondary objectives will be to determine biochemical efficacy of Vorinostat to increase
      expression of NPC1 protein and normalize lipid and protein biomarkers.  This study will
      enroll up to 12 NPC1 patients and test the safety of two dose levels (200 and 400 mg).  Drug
      will be administered on a 3 days on/4 days off schedule for 3 months at each dose level.
      Patients will be evaluated at the NIH Clinical Center at 0, 3 and 6 months. Safety will be
      assessed by adverse events (AEs), clinical laboratory tests and physical examinations.
      Biochemical efficacy will be assessed by measurement of serum and cerebral spinal fluid
      biomarkers. Clinical efficacy will be evaluated by audiologic testing, assessment ataxia,
      and swallowing studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the safety and tolerability of oral Vorinostat therapy in Niemann-Pick Disease, type C1</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain pilot data on Plasma and cerebrospinal fluid biomarkers and on Potential clinical endpoints</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neimann-Pick Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>N/A</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:

          1. Aged greater than or equal to 18 and less than or equal to 60 years old at time of
             enrollment, either gender, and any ethnicity.

          2. Diagnosis of NPC1 based upon one of the following:

               -  Two NPC1 mutations;

               -  Positive filipin staining and at least one NPC1 mutation;

               -  Vertical supranuclear gaze palsy (VSNGP) in combination with either:

               -  One NPC1 mutation, or

               -  Positive filipin staining and no NPC2 mutations.

          3. Patients with at least one neurological manifestation of NPC1. For example, but not
             limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia,
             dystonia, seizures, dysarthria, or dysphagia.

          4. A patient   s cultured skin fibroblasts when treated with 10   M Vorinostat must
             exhibit a reduction in the filipin lysosomal storage organelle ratio equivalent to
             75% of the response measured in GM3123 fibroblasts.

          5. Ability to travel to the NIH Clinical Center repeatedly for evaluation and follow-up.

          6. If taking miglustat, the patient must have been taking a constant dose of the
             medication for no less than three months prior to baseline evaluation and must be
             willing to maintain that dose level for the duration of the trial.

          7. Willing to discontinue all non-prescription supplements, with the exception of an
             age-appropriate multivitamin.

          8. Women of reproductive age must be willing to use an effective method of contraception
             for the duration of the trial.

          9. Willing to participate in all aspects of trial design including serial blood and CSF
             collections.

        EXCLUSION CRITERIA:

          1. Aged below 18 or above 60 years of age at enrollment in the trial.

          2. Severe manifestations of NPC1 that would interfere with the patient   s ability to
             comply with the requirements of this protocol.

          3. Neurologically asymptomatic patients.

          4. Patients who have received any form of cyclodextrin or an HDACi in an attempt to
             treat NPC1.

          5. History of hypersensitivity reactions to Vorinostat or components of the formulation.

          6. Pregnancy or breastfeeding at any time during the study.

          7. Patients with suspected infection of the CNS or any systemic infection.

          8. Neutropenia, defined as an absolute neutrophil count (ANC) of less than 1,500 per
             microliter.

          9. Thrombocytopenia defined as a platelet count less than 75,000 per microliter, or a
             history of greater than or equal to grade 2 thrombocytopenia (50,000-75,000
             platelets/microliter).

         10. Prior use of anticoagulants or history/presence of a bleeding disorder.

         11. Hepatic laboratory parameters (aspartate aminotransferase (AST), alanine
             aminotransferase, (ALT)) greater than four-times upper limit of normal.

         12. Presence of anemia defined as two standard deviations below normal for age and
             gender.

         13. Serum creatinine level greater than 1.5 times the upper limit of normal.

         14. Hematuria on a single urinalysis, as defined by the American Urological Association
             (AUA) as five or more red blood cells per high-power field on microscopic evaluation
             of urinary sediment from a properly collected urinalysis specimen. The patient will
             not be excluded if two subsequent urine specimens are negative for hematuria as
             defined by the AUA.

         15. Proteinuria (1+ protein on urinalysis) unless evaluated and classified as benign by
             patient   s primary medical provider.

         16. Active pulmonary disease, oxygen requirement or clinically significant history of
             decreased blood oxygen saturation, pulmonary therapy, or requiring active suction.

         17. Subjects will be excluded if:

               1. Baseline QTc is &gt; 450 ms

               2. There is a history of risk factors for torsades de pointes (familial long QT
                  syndrome, hypokalemia, heart failure, left ventricular hypertrophy or
                  bradycardia).

               3. The use of concomitant medications known to prolong the QTc interval

         18. Patients unable to complete a behavioral audiologic evaluation including pure-tone
             threshold assessment (500 Hz to 8000 Hz).

         19. Patients with uncontrolled seizures per either of the criteria below.

               1. Unstable frequency, type or duration of seizures.  Quantified by a seizure log
                  over the two months prior to enrollment.

               2. Patients requiring antiepileptic medication changes (other than dose adjustments
                  for weight) in the two months prior to enrollment, or requiring three or more
                  antiepileptic medications to control seizures.

         20. Use of another HDAC inhibitor or compounds with established HDAC inhibitory activity,
             including valproic acid, unless discontinued at least 2 months prior to enrollment.

         21. History of a thromboembolic event (such as DVT or Pulmonary embolism).

         22. Diabetes or a fasting glucose &gt; 100.

         23. Patients, who in the opinion of the investigators, are unable to comply with the
             protocol or have specific health concerns that would potentially increase the risk of
             participation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Forbes D Porter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole M Farhat, C.R.N.P.</last_name>
    <phone>(301) 594-1765</phone>
    <email>nicole.farhat@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Forbes D Porter, M.D.</last_name>
    <phone>(301) 435-4432</phone>
    <email>fdporter@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@mail.cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2014-CH-0102.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Vanier MT. Niemann-Pick diseases. Handb Clin Neurol. 2013;113:1717-21. doi: 10.1016/B978-0-444-59565-2.00041-1. Review.</citation>
    <PMID>23622394</PMID>
  </reference>
  <reference>
    <citation>Ory DS. Niemann-Pick type C: a disorder of cellular cholesterol trafficking. Biochim Biophys Acta. 2000 Dec 15;1529(1-3):331-9. Review. No abstract available.</citation>
    <PMID>11111100</PMID>
  </reference>
  <reference>
    <citation>SÃ©vin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, Sedel F. The adult form of Niemann-Pick disease type C. Brain. 2007 Jan;130(Pt 1):120-33. Epub 2006 Sep 26. Review.</citation>
    <PMID>17003072</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>April 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Niemann Pick Disease, Type C1</keyword>
  <keyword>Phase I, Phase 2</keyword>
  <keyword>Vorinostat</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
